{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:58:50Z","timestamp":1788829130170,"version":"build-2803163510"},"reference-count":146,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>As immunotherapy continues to push the envelope, it has had transformative success in malignancies such as melanoma and lung cancer. However, in contrast to these cancers, implementing immunotherapy in prostate cancer (PCa) still presents considerable difficulties. PCa itself is not sensitive to immunotherapy. The low response rate of PCa to immunotherapy cannot be attributed to a single mechanism. Instead, it results from the interplay of multiple adverse factors. These include the tumor\u2019s inherently low immunogenicity and the highly immunosuppressive properties of its tumor microenvironment. Taken together, these features create a \u201cperfect storm\u201d that severely limits the efficacy of immunotherapy. In this review, we comprehensively assess the latest advances in PCa immunotherapy, encompassing cancer vaccines, immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cell (CAR-T) therapy, and various combination regimens. We also summarize their limited efficacy observed in clinical practice to date. Furthermore, we explore the underlying mechanisms contributing to the limited effectiveness of immunotherapy in PCa, with a focus on intrinsic molecular features, the immunosuppressive microenvironment, and key signaling pathways. Through an in-depth review of previous studies, we aim to provide a theoretical foundation and strategic guidance to enhance the effectiveness of immunotherapy for PCa and to facilitate the development and translation of more targeted and effective immunotherapeutic interventions.<\/jats:p>","DOI":"10.4103\/aja202591","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:00:07Z","timestamp":1770724807000},"page":"345-358","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer"],"prefix":"10.4103","volume":"28","author":[{"given":"Shan-Shan","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China"},{"name":"Key Laboratory of Elemene Anti-Cancer Traditional Chinese Medicine and Zhejiang Provincial Collaborative Innovation Center of Traditional Chinese Medicine, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Da","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China"},{"name":"Key Laboratory of Elemene Anti-Cancer Traditional Chinese Medicine and Zhejiang Provincial Collaborative Innovation Center of Traditional Chinese Medicine, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Hua","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, China"},{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China"},{"name":"Key Laboratory of Elemene Anti-Cancer Traditional Chinese Medicine and Zhejiang Provincial Collaborative Innovation Center of Traditional Chinese Medicine, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"R1-20260702","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260702","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now","volume":"41","author":"Long","year":"2023","journal-title":"J Clin Oncol"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40164-022-00312-y","article-title":"Immunotherapy in patients with metastatic castration-resistant prostate cancer: a meta-analysis of data from 7 phase III studies and 3 phase II studies","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"R8-20260702","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/vaccines12121384","article-title":"Vaccine therapies for prostate cancer: current status and future outlook","volume":"12","author":"Zhou","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat Commun"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.tem.2024.12.003","article-title":"Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer","volume":"36","author":"Brea","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"R11-20260702","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/cells10113165","article-title":"What do we have to know about PD-L1 expression in prostate cancer?A systematic literature review. Part 2: clinic-pathologic correlations","volume":"10","author":"Palicelli","year":"2021","journal-title":"Cells"},{"key":"R12-20260702","doi-asserted-by":"crossref","first-page":"15330338211052154","DOI":"10.1177\/15330338211052154","article-title":"Exploration of the tumor mutational burden as a prognostic biomarker and related hub gene identification in prostate cancer","volume":"20","author":"Wang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"R13-20260702","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1097-0045(19971201)33:4<233::AID-PROS2>3.0.CO;2-I","article-title":"MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma","volume":"33","author":"Bander","year":"1997","journal-title":"Prostate"},{"key":"R14-20260702","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s43018-021-00227-3","article-title":"Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression","volume":"2","author":"Lopez-Bujanda","year":"2021","journal-title":"Nat Cancer"},{"key":"R15-20260702","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2174\/1389450120666190123141553","article-title":"A review of preclinical experiments toward targeting M2 macrophages in prostate cancer","volume":"20","author":"Seif","year":"2019","journal-title":"Curr Drug Targets"},{"key":"R16-20260702","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"R17-20260702","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"R18-20260702","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"key":"R19-20260702","doi-asserted-by":"crossref","first-page":"104276","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"R20-20260702","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2018.02.007","article-title":"First report of prostate-specific membrane antigen-targeted immunotherapy in prostate cancer: the future is bright","volume":"73","author":"Lamb","year":"2018","journal-title":"Eur Urol"},{"key":"R21-20260702","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11206840-000000000-00000","article-title":"Sipuleucel-T: in metastatic castration-resistant prostate cancer","volume":"71","author":"Plosker","year":"2011","journal-title":"Drugs"},{"key":"R22-20260702","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"R23-20260702","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"key":"R24-20260702","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R25-20260702","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/13543780902997928","article-title":"Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"R26-20260702","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2326-6066.CIR-13-0108","article-title":"Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer","volume":"2","author":"Gulley","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R27-20260702","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.2016.69.7748","article-title":"Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of prostvac in men with metastatic castration-resistant prostate cancer","volume":"35","author":"Kantoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"R28-20260702","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"R29-20260702","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.urolonc.2005.08.021","article-title":"Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer","volume":"24","author":"Simons","year":"2006","journal-title":"Urol Oncol"},{"key":"R30-20260702","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11934-010-0106-8","article-title":"Update: immunological strategies for prostate cancer","volume":"11","author":"Drake","year":"2010","journal-title":"Curr Urol Rep"},{"key":"R31-20260702","first-page":"26","article-title":"A Phase III Trial of GVAX Immunotherapy for Prostate Cancer Versus Docetaxel Plus Prednisone in Asymptomatic, Castration-Resistant Prostate Cancer (CRPC)","author":"Higano","year":"2009","journal-title":"Proceedings of the 2009 Genitourinary Cancer Symposium Orlando: American Society of Clinical Oncology"},{"key":"R32-20260702","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"R33-20260702","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"R34-20260702","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"R35-20260702","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"R36-20260702","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"R37-20260702","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/pcan.2015.39","article-title":"Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance","volume":"18","author":"Martin","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R38-20260702","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R39-20260702","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.euo.2024.05.013","article-title":"Pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: results from KEYNOTE-365 cohort D","volume":"8","author":"Yu","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"R40-20260702","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.euo.2023.10.008","article-title":"Pembrolizumab and enzalutamide in patients with abiraterone acetate-pretreated metastatic castration-resistant prostate cancer: cohort C of the phase 1b\/2 KEYNOTE-365 study","volume":"7","author":"Yu","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"R41-20260702","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort A study","volume":"83","author":"Yu","year":"2023","journal-title":"Eur Urol"},{"key":"R42-20260702","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","article-title":"Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study","volume":"82","author":"Yu","year":"2022","journal-title":"Eur Urol"},{"key":"R43-20260702","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"R44-20260702","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.annonc.2025.05.008","article-title":"Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study","volume":"36","author":"Gratzke","year":"2025","journal-title":"Ann Oncol"},{"key":"R45-20260702","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial","volume":"43","author":"Petrylak","year":"2025","journal-title":"J Clin Oncol"},{"key":"R46-20260702","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"key":"R47-20260702","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"R48-20260702","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"R49-20260702","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1078-0432.CCR-24-1612","article-title":"Randomized phase II study of durvalumab with or without tremelimumab in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Winquist","year":"2025","journal-title":"Clin Cancer Res"},{"key":"R50-20260702","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R51-20260702","doi-asserted-by":"crossref","first-page":"e70111","DOI":"10.1002\/mco2.70111","article-title":"Avelumab mediates antibody-dependent cellular cytotoxicity against monocyte-derived dendritic cells through natural killer cells","volume":"6","author":"Sauerer","year":"2025","journal-title":"MedComm (2020)"},{"key":"R52-20260702","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R53-20260702","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41391-022-00524-7","article-title":"A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer","volume":"25","author":"Brown","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R54-20260702","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur Urol"},{"key":"R55-20260702","doi-asserted-by":"crossref","first-page":"8355","DOI":"10.1002\/cam4.3445","article-title":"Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: a preliminary study","volume":"9","author":"Fukushima","year":"2020","journal-title":"Cancer Med"},{"key":"R56-20260702","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1038\/537S109a","article-title":"Immunotherapy: controlled attack","volume":"537","author":"Schmidt","year":"2016","journal-title":"Nature"},{"key":"R57-20260702","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R58-20260702","doi-asserted-by":"crossref","first-page":"e006127","DOI":"10.1136\/jitc-2022-006127","article-title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: checkMate 817","volume":"11","author":"Ready","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R59-20260702","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"R60-20260702","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"R61-20260702","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"key":"R62-20260702","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"R63-20260702","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"R64-20260702","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"R65-20260702","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"R66-20260702","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eururo.2019.08.014","article-title":"Challenges and prospects of chimeric antigen receptor T-cell therapy for metastatic prostate cancer","volume":"77","author":"Gorchakov","year":"2020","journal-title":"Eur Urol"},{"key":"R67-20260702","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"R68-20260702","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"R69-20260702","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"R70-20260702","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5694\/mja2.12046","article-title":"Radiotherapy and immunotherapy: a synergistic effect in cancer care","volume":"210","author":"Turgeon","year":"2019","journal-title":"Med J Aust"},{"key":"R71-20260702","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R72-20260702","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R73-20260702","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"R74-20260702","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"R75-20260702","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"R76-20260702","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"R77-20260702","doi-asserted-by":"crossref","first-page":"e001556","DOI":"10.1136\/jitc-2020-001556","article-title":"Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer","volume":"9","author":"Madan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R78-20260702","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R79-20260702","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.7150\/thno.73152","article-title":"Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"key":"R80-20260702","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/CBM-230090","article-title":"PD-1 inhibitor combined with docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K\/AKT\/NFKB-P65\/PD-L1 signaling pathway","volume":"40","author":"Zhou","year":"2024","journal-title":"Cancer Biomark"},{"key":"R81-20260702","doi-asserted-by":"crossref","first-page":"215829","DOI":"10.1016\/j.canlet.2022.215829","article-title":"Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING\/MAVS signaling pathway","volume":"545","author":"Zhang","year":"2022","journal-title":"Cancer Lett"},{"key":"R82-20260702","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1007\/s00432-022-04248-y","article-title":"Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs","volume":"148","author":"Zhang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R83-20260702","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone versus placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol"},{"key":"R84-20260702","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"R85-20260702","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"R86-20260702","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"R87-20260702","doi-asserted-by":"crossref","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R88-20260702","doi-asserted-by":"crossref","first-page":"e237096","DOI":"10.6004\/jnccn.2023.7096","article-title":"Long-term outcomes of dMMR\/MSI-H rectal cancer treated with anti-PD-1-based immunotherapy as curative-intent treatment","volume":"22","author":"Yu","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R89-20260702","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12957-021-02325-z","article-title":"The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer","volume":"19","author":"He","year":"2021","journal-title":"World J Surg Oncol"},{"key":"R90-20260702","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"R91-20260702","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","article-title":"Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer","volume":"188","author":"Haffner","year":"2018","journal-title":"Am J Pathol"},{"key":"R92-20260702","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.3390\/cells10113166","article-title":"What do we have to know about PD-L1 expression in prostate cancer?A systematic literature review. Part 1: focus on immunohistochemical results with discussion of pre-analytical and interpretation variables","volume":"10","author":"Palicelli","year":"2021","journal-title":"Cells"},{"key":"R93-20260702","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0090-4295(99)80301-X","article-title":"Loss of HLA class I expression in prostate cancer: implications for immunotherapy","volume":"46","author":"Blades","year":"1995","journal-title":"Urology"},{"key":"R94-20260702","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","article-title":"Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer","volume":"15","author":"Chesner","year":"2025","journal-title":"Cancer Discov"},{"key":"R95-20260702","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"key":"R96-20260702","doi-asserted-by":"crossref","first-page":"949072","DOI":"10.1155\/2011\/949072","article-title":"Cross-talk between apolipoprotein E and cytokines","volume":"2011","author":"Zhang","year":"2011","journal-title":"Mediators Inflamm"},{"key":"R97-20260702","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.7150\/thno.109994","article-title":"Apolipoprotein E promotes primary resistance to AR-targeted therapy via inducing TRIM25-mediated AR ubiquitination and sensitizes immunotherapy in prostate cancer","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"key":"R98-20260702","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1158\/0008-5472.CAN-22-2405","article-title":"Androgen signaling contributes to sex differences in cancer by inhibiting NF-\u03baB activation in T cells and suppressing antitumor immunity","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res"},{"key":"R99-20260702","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and Wnt signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R100-20260702","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R101-20260702","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"R102-20260702","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-023-00594-z","article-title":"The Akt\/mTOR and MNK\/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells","volume":"4","author":"Brina","year":"2023","journal-title":"Nat Cancer"},{"key":"R103-20260702","doi-asserted-by":"crossref","first-page":"217090","DOI":"10.1016\/j.canlet.2024.217090","article-title":"Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer","volume":"598","author":"Liu","year":"2024","journal-title":"Cancer Lett"},{"key":"R104-20260702","doi-asserted-by":"crossref","first-page":"116154","DOI":"10.1016\/j.bcp.2024.116154","article-title":"Wnt signaling: modulating tumor-associated macrophages and related immunotherapeutic insights","volume":"223","author":"Yuan","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"R105-20260702","doi-asserted-by":"crossref","first-page":"eaaz6105","DOI":"10.1126\/sciadv.aaz6105","article-title":"Reprogramming of tumor-associated macrophages by targeting \u03b2-catenin\/FOSL2\/ARID5A signaling: a potential treatment of lung cancer","volume":"6","author":"Sarode","year":"2020","journal-title":"Sci Adv"},{"key":"R106-20260702","doi-asserted-by":"crossref","first-page":"e2402903121","DOI":"10.1073\/pnas.2402903121","article-title":"Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization","volume":"121","author":"Yu","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R107-20260702","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ijbiomac.2022.09.203","article-title":"Non-coding RNAs targeting notch signaling pathway in cancer: from proliferation to cancer therapy resistance","volume":"222","author":"Hashemi","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"R108-20260702","doi-asserted-by":"crossref","first-page":"e14562","DOI":"10.1111\/cbdd.14562","article-title":"In vitro modulation the Notch pathway by piperine: a therapeutic strategy for docetaxel-resistant and non-resistant prostate cancer","volume":"103","author":"Wang","year":"2024","journal-title":"Chem Biol Drug Des"},{"key":"R109-20260702","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/ijms24010164","article-title":"Age- and stage-dependent prostate cancer aggressiveness associated with differential notch signaling","volume":"24","author":"Orzechowska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R110-20260702","doi-asserted-by":"crossref","first-page":"9235837","DOI":"10.1155\/2022\/9235837","article-title":"SOX8 knockdown overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting the notch signaling pathway","volume":"2022","author":"Du","year":"2022","journal-title":"Biomed Res Int"},{"key":"R111-20260702","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-0716-2201-8_18","article-title":"Metastasis model to test the role of notch signaling in prostate cancer","volume":"2472","author":"Liu","year":"2022","journal-title":"Methods Mol Biol"},{"key":"R112-20260702","doi-asserted-by":"crossref","first-page":"e175217","DOI":"10.1172\/JCI175217","article-title":"Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer","volume":"134","author":"Ku","year":"2024","journal-title":"J Clin Invest"},{"key":"R113-20260702","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"R114-20260702","first-page":"10","article-title":"Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer","volume":"7","author":"Liakou","year":"2007","journal-title":"Cancer Immun"},{"key":"R115-20260702","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-5876-12-30","article-title":"Tumor infiltrating B-cells are increased in prostate cancer tissue","volume":"12","author":"Woo","year":"2014","journal-title":"J Transl Med"},{"key":"R116-20260702","first-page":"2095","article-title":"A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour","volume":"16","author":"Lipponen","year":"1996","journal-title":"Anticancer Res"},{"key":"R117-20260702","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","article-title":"Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses","volume":"14","author":"Hirz","year":"2023","journal-title":"Nat Commun"},{"key":"R118-20260702","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pros.24524","article-title":"Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile","volume":"83","author":"Adorno","year":"2023","journal-title":"Prostate"},{"key":"R119-20260702","doi-asserted-by":"crossref","first-page":"e2305724","DOI":"10.1002\/advs.202305724","article-title":"Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity","volume":"11","author":"Bian","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"R120-20260702","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm.2236","article-title":"Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance","volume":"16","author":"Tanaka","year":"2010","journal-title":"Nat Med"},{"key":"R121-20260702","doi-asserted-by":"crossref","first-page":"e1423170","DOI":"10.1080\/2162402X.2017.1423170","article-title":"PD-L1 expression is regulated by both DNA methylation and NF-\u03baB during EMT signaling in non-small cell lung carcinoma","volume":"7","author":"Asgarova","year":"2018","journal-title":"Oncoimmunology"},{"key":"R122-20260702","doi-asserted-by":"crossref","first-page":"e002138","DOI":"10.1136\/jitc-2020-002138","article-title":"N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells","volume":"9","author":"Sun","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R123-20260702","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cellimm.2009.03.004","article-title":"Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors","volume":"257","author":"Lucas","year":"2009","journal-title":"Cell Immunol"},{"key":"R124-20260702","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R125-20260702","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"R126-20260702","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-07-2056","article-title":"Enhanced functionality of CD4+CD25highFoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer","volume":"14","author":"Yokokawa","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R127-20260702","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/JLB.4RU0819-150RR","article-title":"Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer: MDSCs and immune system in prostate cancer","volume":"107","author":"Sanaei","year":"2020","journal-title":"J Leukoc Biol"},{"key":"R128-20260702","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","article-title":"Macrophages at the interface of the co-evolving cancer ecosystem","volume":"186","author":"Kloosterman","year":"2023","journal-title":"Cell"},{"key":"R129-20260702","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.7150\/ijbs.73141","article-title":"Tumor-associated macrophages in direct contact with prostate cancer cells promote malignant proliferation and metastasis through Notch1 pathway","volume":"18","author":"Shi","year":"2022","journal-title":"Int J Biol Sci"},{"key":"R130-20260702","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"R131-20260702","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1080\/07853890.2021.1924396","article-title":"M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer","volume":"53","author":"JiaWei","year":"2021","journal-title":"Ann Med"},{"key":"R132-20260702","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"R133-20260702","doi-asserted-by":"crossref","first-page":"101420","DOI":"10.1016\/j.xcrm.2024.101420","article-title":"PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep Med"},{"key":"R134-20260702","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"R135-20260702","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/0008-5472.CAN-24-0932","article-title":"YAP1 inhibition induces phenotype switching of cancer-associated fibroblasts to tumor suppressive in prostate cancer","volume":"84","author":"Song","year":"2024","journal-title":"Cancer Res"},{"key":"R136-20260702","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","article-title":"The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment","volume":"10","author":"Monteran","year":"2019","journal-title":"Front Immunol"},{"key":"R137-20260702","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R138-20260702","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1038\/s41467-024-53233-1","article-title":"Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"R139-20260702","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-18-0751","article-title":"CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer","volume":"7","author":"Maeda","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"R140-20260702","doi-asserted-by":"crossref","first-page":"e003731","DOI":"10.1136\/jitc-2021-003731","article-title":"Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer","volume":"10","author":"Maeda","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R141-20260702","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/0008-5472.CAN-09-2984","article-title":"Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model","volume":"70","author":"Terada","year":"2010","journal-title":"Cancer Res"},{"key":"R142-20260702","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-21-0299","article-title":"Single-cell analysis reveals EP4 as a target for restoring T-cell infiltration and sensitizing prostate cancer to immunotherapy","volume":"28","author":"Peng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R143-20260702","doi-asserted-by":"crossref","first-page":"189005","DOI":"10.1016\/j.bbcan.2023.189005","article-title":"Adenosine in cancer immunotherapy: taking off on a new plane","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R144-20260702","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R145-20260702","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"R146-20260702","doi-asserted-by":"crossref","first-page":"e004761","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 Checkmate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:06Z","timestamp":1787166666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":146,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202591","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"2025-06-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}